trilaciclib: Clinical Trials

6 trials of trilaciclib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Trilaciclib, Saline (0.9% NaCl) - Limited Stage Small Cell Lung Cancer
Phase 3RecruitingPharmacosmos A/S1202026-09-012026-10-02
A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression
Phase 3Active not recruitingJiangsu Simcere Pharmaceutical Co., Ltd.1062026-06-172026-10-19
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib, Tislelizumab, Cisplatin, Gemcitabine - Bladder Cancer
Phase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2102025-10-012025-02-21
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
Trilaciclib, carboplatin, etoposide,or Topotecan, placebo, carboplatin, etoposide,or Topotecan - Extensive-stage Small-cell Lung Cancer
Phase 3CompletedJiangsu Simcere Pharmaceutical Co., Ltd.952021-05-252024-07-10
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
Trilaciclib, Placebo, Gemcitabine - TNBC - Triple-Negative Breast Cancer, Breast Cancer
Phase 3CompletedG1 Therapeutics, Inc.1942021-05-142024-08-01
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Trilaciclib, Placebo - Colorectal Cancer Metastatic, Myelosuppression-Adult
Phase 3TerminatedG1 Therapeutics, Inc.3262021-01-062024-11-26

Conditions studied

Small Cell Lung Carcinoma (2)  ·  Breast Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

G1 Therapeutics, Inc. (2)  ·  Jiangsu Simcere Pharmaceutical Co., Ltd. (2)  ·  Pharmacosmos A/S (1)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)

Countries

China (5)  ·  United States (3)  ·  Poland (2)  ·  Spain (2)  ·  Ukraine (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  France (1)  ·  Georgia (1)  ·  Hungary (1)  ·  Italy (1)  ·  Moldova (1)  ·  Russia (1)  ·  United Kingdom (1)

Top investigators

Tianxin Lin, Ph.D (1)  ·  Ying Cheng, Doctor (1)

Results publications

PMID 36135712, PMID 39579142